Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

An Observational Study of Patients With Dermatologic Disease

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.

Participants needed: 2,000,000
Trial details
Biological sex: AllType: ObservationalSponsor: Target PharmaSolutions, Inc.Updated: Aug 5, 2026Locations: 3Duration: 15 Years
Eligibility criteria

Adult or pediatric participants managed for DD invited to participate OR a provi... [+1]

Participant withdrew consent; Failure to complete activities as required per the...

Status: Not yet recruiting

An Observational Study of Patients With Autoimmune Disease

TARGET-AUTOIMMUNE is an observational research study to conduct a comprehensive review of outcomes for patients with autoimmune and related diseases. .

Participants needed: 500,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Target PharmaSolutions, Inc.Updated: Nov 20, 2024
Eligibility criteria

Death [+8]

Status: Not yet recruiting

An Observational Study of Patients Living With Chronic Neurological Diseases

TARGET-NEURO is an observational research study to conduct a comprehensive review of outcomes for patients living with chronic neurological diseases: Alzheimer's disease and related dementia (ADRD), mild cognitive impairment (MCI), Parkinson's disease (PD), and multiple sclerosis (MS).

Participants needed: 1,500,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Target PharmaSolutions, Inc.Updated: Nov 20, 2024
Eligibility criteria

Death [+13]